Tristel's strategy is to sustain double-digit growth and deliver long-term value by extending leadership in point-of-care medical device disinfection and sporicidal surface disinfection. Operating from Snailwell near Cambridge with approximately 270 employees across 16 subsidiaries, the company maintains a debt-free balance sheet and targets EBITDA margins of at least 25%.
Cyborg Score Rationale
The company reported strong financial results, achieved FDA clearance of Tristel OPH, and published independent clinical evidence with leading institutions like Mayo Clinic. Strong cash generation and continued disciplined execution enabled dividend increases while maintaining a debt-free balance sheet. Recurring revenue model in infection prevention provides stable growth trajectory.
Top Insights
FDA clearance of Tristel OPH and recognition of chlorine dioxide foam in updated US standards expand addressable market
New product launches including VISICLEAN™ position company for sustained revenue growth
Global distribution through 16 subsidiaries selling into 40+ countries with ~270 employees demonstrates scalability
Debt-free business with no leverage and progressive dividend policy indicates financial discipline and shareholder focus
Named Competitors
Medical Device Sterilization/Disinfection — Larger competitors offering alternative sterilization/disinfection solutions